Cautious Hold Rating on HilleVax, Inc: Balancing Strong Cash Reserves With Strategic Uncertainty
Stifel Maintains HilleVax(HLVX.US) With Hold Rating, Maintains Target Price $3
H.C. Wainwright Maintains HilleVax(HLVX.US) With Hold Rating, Maintains Target Price $2
HilleVax, Inc: Analyst Maintains Hold Rating Amid Vaccine Trial Setback and Strategic Shift
HilleVax, Inc.: Prudent Cost Management Amidst Trial Setbacks – Hold Rating Justified
HilleVax Analyst Ratings
HilleVax, Inc: Hold Rating Amid Vaccine Efficacy Concerns and Financial Uncertainty
Analysts Offer Insights on Healthcare Companies: Verastem (VSTM), HilleVax, Inc (HLVX) and Schrodinger (SDGR)
Stifel Downgrades HilleVax to Hold From Buy, Adjusts Price Target to $3 From $34
HilleVax, Inc: Hold Rating Justified by Clinical Trial Setbacks and Strategic Uncertainties
Hold Rating on HilleVax as Clinical Setbacks Complicate Investment Outlook
Analysts Conflicted on These Healthcare Names: HilleVax, Inc (HLVX), UnitedHealth (UNH) and Morphic Holding (MORF)
HilleVax Analyst Ratings
HilleVax Analyst Ratings
HilleVax Analyst Ratings
Analysts Offer Insights on Healthcare Companies: AbSci (ABSI), HilleVax, Inc (HLVX) and Cabaletta Bio (CABA)
Stifel Adjusts HilleVax Price Target to $34 From $30, Maintains Buy Rating
HC Wainwright & Co. Reiterates Buy on HilleVax, Maintains $28 Price Target
HilleVax Analyst Ratings
HilleVax, Inc's HIL-214 Vaccine Candidate Promises Broad Protection Against Norovirus, Justifying Buy Rating